絲裂原活化蛋白激酶激酶抑制劑相關視網膜病變1例_Chinese Journal of Ocular Fundus Diseases

Authors：

杜冬菊 ^1,2 , 劉思唯 ¹ , 崔金利 ¹ , 劉欣雨 ¹ , 何嘉萱 ¹ , 劉澤浩 ¹ ,  林英 ¹

1. ;
2. ;

Corresponding?author：

林英, Email: linying@gzzoc.com

Keywords：

妥拉美替尼; 絲裂原活化蛋白激酶激酶抑制劑相關性視網膜病變; 漿液性神經上皮層脫離; 病例報告

DOI：

10.3760/cma.j.cn511434-20250724-00321

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Citation： 杜冬菊, 劉思唯, 崔金利, 劉欣雨, 何嘉萱, 劉澤浩, 林英. 絲裂原活化蛋白激酶激酶抑制劑相關視網膜病變1例. Chinese Journal of Ocular Fundus Diseases, 2026, 42(8): 704-705. doi: 10.3760/cma.j.cn511434-20250724-00321 Copy

1.	Liu Y, Cheng Y, Huang G, et al. Preclinical characterization of tunlametinib, a novel, potent, and selective MEK inhibitor[J/OL]. Front Pharmacol, 2023, 14: 1271268[2023-09-21]. https://pubmed.ncbi.nlm.nih.gov/37808191/. DOI: 10.3389/fphar.2023.1271268.
2.	Keam SJ. Tunlametinib: first approval[J]. Drugs, 2024, 84(8): 1005-1010. DOI: 10.1007/s40265-024-02072-x.
3.	Stjepanovic N, Velazquez-Martin J, Bedard P. Ocular toxicities of MEK inhibitors and other targeted therapies[J]. Ann Oncol, 2016, 27(6): 998-1005. DOI: 10.1093/annonc/mdw100.
4.	Méndez-Martínez S, Calvo P, Ruiz-Moreno ó, et al. Ocular adverse events associated with MEK inhibitors[J]. Retina, 2019, 39(8): 1435-1450. DOI: 10.1097/IAE.0000000000002451.
5.	Francis JH, Habib LA, Abramson DH, et al. Clinical and morphologic characteristics of MEK inhibitor-associated retinopathy: differences from central serous chorioretinopathy[J]. Ophthalmology, 2017, 124(12): 1788-1798. DOI: 10.1016/j.ophtha.2017.05.038.
6.	Arora S, Surakiatchanukul T, Arora T, et al. Retinal toxicities of systemic anticancer drugs[J]. Surv Ophthalmol, 2022, 67(1): 97-148. DOI: 10.1016/j.survophthal.2021.05.007.
7.	Hecquet C, Lefevre G, Valtink M, et al. Activation and role of MAP kinase-dependent pathways in retinal pigment epithelial cells: ERK and RPE cell proliferation[J]. Invest Ophthalmol Vis Sci, 2002, 43(9): 3091-3098.

1. Liu Y, Cheng Y, Huang G, et al. Preclinical characterization of tunlametinib, a novel, potent, and selective MEK inhibitor[J/OL]. Front Pharmacol, 2023, 14: 1271268[2023-09-21]. https://pubmed.ncbi.nlm.nih.gov/37808191/. DOI: 10.3389/fphar.2023.1271268.
2. Keam SJ. Tunlametinib: first approval[J]. Drugs, 2024, 84(8): 1005-1010. DOI: 10.1007/s40265-024-02072-x.
3. Stjepanovic N, Velazquez-Martin J, Bedard P. Ocular toxicities of MEK inhibitors and other targeted therapies[J]. Ann Oncol, 2016, 27(6): 998-1005. DOI: 10.1093/annonc/mdw100.
4. Méndez-Martínez S, Calvo P, Ruiz-Moreno ó, et al. Ocular adverse events associated with MEK inhibitors[J]. Retina, 2019, 39(8): 1435-1450. DOI: 10.1097/IAE.0000000000002451.
5. Francis JH, Habib LA, Abramson DH, et al. Clinical and morphologic characteristics of MEK inhibitor-associated retinopathy: differences from central serous chorioretinopathy[J]. Ophthalmology, 2017, 124(12): 1788-1798. DOI: 10.1016/j.ophtha.2017.05.038.
6. Arora S, Surakiatchanukul T, Arora T, et al. Retinal toxicities of systemic anticancer drugs[J]. Surv Ophthalmol, 2022, 67(1): 97-148. DOI: 10.1016/j.survophthal.2021.05.007.
7. Hecquet C, Lefevre G, Valtink M, et al. Activation and role of MAP kinase-dependent pathways in retinal pigment epithelial cells: ERK and RPE cell proliferation[J]. Invest Ophthalmol Vis Sci, 2002, 43(9): 3091-3098.

Previous Article
莫西沙星相關雙眼急性虹膜脫色素1例
Next Article
兒童視網膜血管炎3例

Chinese Journal of Ocular Fundus Diseases

絲裂原活化蛋白激酶激酶抑制劑相關視網膜病變1例

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content